RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

Vaccine
Fatma DoenerUlrike Gnad-Vogt

Abstract

We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen. The primary objective was to assess the safety and reactogenicity of various dose levels of CV8102 alone or mixed with Rabipur® in healthy 18-40 year-old male volunteers. A secondary objective was to assess the immune-enhancing potential of bedside-mixes of CV8102 with fractional doses of Rabipur® by measuring induction of rabies virus neutralising titres (VNTs). Fifty-six volunteers received 50-100 μg CV8102 alone (n = 11), bedside-mixed CV8102 and Rabipur® (n = 20), or Rabipur® alone (n = 25; control). When given alone or mixed with Rabipur® CV8102 caused mostly Grade 1 or 2 local or systemic reactogenicity, but no related SAEs. As 100 µg CV8102 was associated with marked CRP increases further dose escalation was stopped. Combining 25-50 µg of CV8102 with fractional doses of Rabipur® significantly improved the kinetics of VNT responses; 50 µg CV8102 also improved the magnitude of VNT responses to 1/10 Rabipur® but caused severe but self-limiting influenza-like sympt...Continue Reading

Citations

Sep 27, 2019·Nature Reviews. Drug Discovery·Claire Vanpouille-BoxLorenzo Galluzzi
Apr 25, 2020·Current Treatment Options in Oncology·Vamsi VarraShlomo A Koyfman
Apr 3, 2020·Pathogens·Konstantin IvanovSvetlana Khaiboullina
Oct 27, 2020·Chembiochem : a European Journal of Chemical Biology·Vassiliki DamakoudiClemens Richert
Mar 24, 2020·European Journal of Medicinal Chemistry·Cindy PatinoteCarine Deleuze-Masquéfa
Mar 8, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sze-Wah TseEric Huang
Jul 16, 2020·Immunity·Sarah M McWhirter, Caroline A Jefferies
Apr 16, 2021·Advanced Drug Delivery Reviews·M Brittany JohnsonKirill A Afonin
Aug 2, 2021·Molecular Aspects of Medicine·Manish PandeyGeetanjali Chawla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.